EUVIMEDEUVIMED entdecken
Crossref

Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups

Amy G Aslamkhan iD, Wen Kang, Karin Otte, Alex Tamburino, Paul J Ciaccio, Beatrice Sacre-Salem, Zoltan Erdos, Yuexia Liang, Richard W Gundersdorf, Bridget Becker, Keith Q Tanis, Todd Pippert und 15 weitere

Toxicological Sciences · 01.08.2026 · 209 (8)

DOI: 10.1093/toxsci/kfag083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 20.07.2026. Verfasst von Amy G Aslamkhan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Nonclinical Drug Safety, Merck & Co., Inc., Rahway, NJ 07065, United States. Hauptthemen laut MEDLINE: Receptors, Aryl Hydrocarbon, Basic Helix-Loop-Helix Proteins, Drug Discovery. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

During lead optimization, off-target activation of the aryl hydrocarbon receptor (AhR) was identified for Compound 25. AhR is a xenobiotic-responsive transcription factor associated with adverse outcomes in rodents (and potentially humans) and modulation of drug metabolism. In rats, marked hepatic induction of AhR target genes, Cyp1a1 and Cyp1a2, was observed following repeat dosing and increased with study duration. Compound 25 was inactive in conventional AhR luciferase reporter assays but induced robust Cyp1a1 expression in metabolically competent rat and human HEPATOPAC cultures, suggesting a metabolism-dependent mechanism. Extensive metabolite profiling demonstrated that Compound 25 undergoes complex oxidative and conjugative metabolism; however, specific AhR-active metabolite(s) could not be identified. AhR involvement was confirmed in vivo using AhR knockout and wild-type rats, in which Cyp1a1/2 induction occurred exclusively in wild-type animals. Chromatin immunoprecipitation further demonstrated increased AhR binding at Cyp1a1/2 promoters following Compound 25 treatment. In rat HEPATOPAC cultures, siRNA-mediated knockdown of Por and Cyb5a attenuated Cyp1a1 induction, supporting a requirement for metabolic competence. Consistent with AhR pathway engagement, induction of CYP1A1 in human HEPATOPAC was reduced by the AhR antagonist CH223191. Collectively, these findings demonstrate that AhR activation associated with Compound 25 is dependent on metabolic transformation and may not be detected in conventional reporter assays lacking metabolic capacity. This work highlights the value of metabolically competent hepatocyte models, combined with short-duration in vivo studies, for identifying and mitigating metabolism-dependent AhR liabilities during drug discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Aryl HydrocarbonBasic Helix-Loop-Helix ProteinsDrug DiscoveryAnimalsHumansCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2MaleRats, Sprague-DawleyRatsHepatocytesLiverEnzyme Induction

Stichwörter der Autor:innen

HEPATOPACaryl hydrocarbon receptor (AhR)chromatin immunoprecipitation (ChIP)de-riskingknockout (KO)metabolite

Substanzen

Receptors, Aryl HydrocarbonCytochrome P-450 CYP1A1Cytochrome P-450 CYP1A2Basic Helix-Loop-Helix ProteinsAhr protein, ratCyp1a2 protein, rat

Autor:innen und Institutionen

  • Nonclinical Drug Safety, Merck & Co., Inc., Rahway, NJ 07065, United States.
  • Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., Rahway, NJ 07065, United States.
  • Data, AI and Genome Sciences, Merck & Co., Inc., Rahway, NJ 07065, United States.
  • Department of Chemistry, Massachusetts Institute of Technology, Boston, MA 02139, United States.
  • Chemistry, Merck & Co., Inc., Rahway, NJ 07065, United States.
  • Neuroscience Discovery, Merck & Co., Inc., Rahway, NJ 07065, United States.

ORCID-Profile: Amy G Aslamkhan, Kara M Pearson

Zitieren

APA

Aslamkhan, A. G., Kang, W., Otte, K., Tamburino, A., Ciaccio, P. J., Sacre-Salem, B., Erdos, Z., Liang, Y., Gundersdorf, R. W., Becker, B., Tanis, K. Q., Pippert, T., Lane, P., Jacob, B., Bleicher, K. B., Wang, Z., Su, M., Pacchione, S., Candito, D., …, & Glaab, W. E. (2026). Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups. Toxicological Sciences, 209(8). https://doi.org/10.1093/toxsci/kfag083

Vancouver

Aslamkhan AG, Kang W, Otte K, Tamburino A, Ciaccio PJ, Sacre-Salem B, et al. Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups. Toxicological Sciences. 2026;209(8). doi:10.1093/toxsci/kfag083

BibTeX
@article{Aslamkhan2026,
  author = {Aslamkhan, Amy G and Kang, Wen and Otte, Karin and Tamburino, Alex and Ciaccio, Paul J and Sacre-Salem, Beatrice and Erdos, Zoltan and Liang, Yuexia and Gundersdorf, Richard W and Becker, Bridget and Tanis, Keith Q and Pippert, Todd and Lane, Pam and Jacob, Binod and Bleicher, Kimberly B and Wang, Zhibin and Su, Ming and Pacchione, Stephen and Candito, David and Simov, Vladimir and Fuller, Peter H and Fell, Matthew J and Ellis, J Michael and Foti, Robert and Pearson, Kara M and Sistare, Frank D and Glaab, Warren E},
  title = {Investigation of a metabolism-dependent aryl hydrocarbon receptor off-target activation for a drug development candidate and a screening strategy for de-risking backups},
  journal = {Toxicological Sciences},
  year = {2026},
  volume = {209},
  number = {8},
  doi = {10.1093/toxsci/kfag083}
}
Kostenlos starten →